Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$3.68 - $10.48
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$40.22M
Enterprise Value-$10.56
Total Cash (Recent Filing)$59.26M
Total Debt (Recent Filing)$2.06M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding9,930,329
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.50Price Target Upside2551.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.25
Revenue Forecast (FY)$1.17M
Bulls Say, Bears Say
Bulls Say
Conservative Recent Balance SheetLow debt relative to equity and conservative leverage give SCYNEXIS financial flexibility to fund clinical programs and absorb ongoing R&D losses without immediate insolvency risk. This durability supports ability to execute multi-quarter development timelines and negotiate partnerships.
Expanded Capital Raising And Resale CapacityShareholder approval to increase authorized shares and an effective S-3 registration materially improves the company’s ability to raise capital efficiently, sell registered shares, and support clinical development or pay milestones without protracted filings, strengthening short-to-medium term runway options.
Pipeline Expansion And Funded RunwayAdding SCY-770 diversifies the pipeline beyond the lead antifungal, reducing single-product concentration risk. The $40M financing extends runway to advance trials, lowering near-term financing pressure and enabling execution of multiple clinical milestones over coming quarters.
Bears Say
Ongoing Negative Cash FlowPersistent negative operating and free cash flow means the business is not self-funding; continued clinical investment and commercialization costs will require external financing. This structural cash burn elevates dilution and refinancing risk over the next several quarters if revenue doesn't recover.
Volatile, Negative ProfitabilitySharp swings from prior profitable years to steep losses and very negative margins signal revenue reliance on lumpy, non-recurring items and weak earnings durability. Sustained negative profitability undermines reinvestment potential and heightens dependence on external capital.
Potential Equity Dilution OverhangLarge registered resale capacity and an expanded equity incentive pool create a durable potential supply of new shares and warrant conversions. That structural overhang raises the likelihood of future dilution, impacting long-term shareholder value and management incentives unless offset by strong cash generation.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $3.68 and its highest was $10.48 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $40.22M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Aug 17, 2026 which is in 25 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on May 11, 2026. The company reported -$3.36 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$2.373.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.51.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,930,329 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$3.36 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went down -5.34%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (2551.52% Upside)
$17.50 (2551.52% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.30%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYX Stock 12 Month Forecast
Average Price Target
$17.50
▲(2551.52% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
24.07% Insiders
19.48% Mutual Funds
― Other Institutional Investors
53.32% Public Companies and
Individual Investors